{"url_path":"/sec/zeox/8-k/2026-07-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-007689-index.html","accession_number":"0001829126-26-007689","cik":"0001557376","ticker":"ZEOX","issuer_name":"Zeo ScientifiX, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-007689-index.html","primary_entity_key":"0001557376","primary_entity_name":"Zeo ScientifiX, Inc."},"word_count":86,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nOn\nJuly 21, 2026, ZEO issued a press release announcing its efforts to strengthen its role within South Florida’s healthcare innovation\necosystem through regenerative biologic research and development, physician education, and scientific collaboration. The press release\nalso highlights the Company’s operations at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida\nand its ongoing initiatives to support scientific exchange and responsible advancement within the regenerative medicine field.\n\n \n\nA\ncopy of the press release is included as **Exhibit 99.1 **to this Report."}